Topics

Articles

Exparel was initially approved in 2011 for single-dose infiltration into a surgical site.

Pacira BioSciences Announces FDA Approval of Expanded Indications for Exparel

The Flowflex COVID-19 Antigen Home Test is the first over-the-counter rapid antigen test for SARS-CoV-2 to gain FDA 510(k) marketing clearance by the FDA.

FDA Grants 510(k) Marketing Clearance to Flowflex COVID-19 Antigen Home Test

Conference presentation explores groundbreaking topics impacting the pharma industry.

Access Insights 2023: A View from DC

Fruquintinib (Fruzaqla) is a significant new therapy for patients who have had limited options to treat metastatic colorectal cancer.

Novel Chemotherapy-Free Fruzaqla Gets FDA Approval for Metastatic Colorectal Cancer 

Conference session discusses the drivers, practical considerations, success factors, and landscape for next-generation pharmacy innovation.

Access Insights 2023: The Pharmacy of the Future 

Ayala Pharmaceuticals’ AL102 is a gamma secretase inhibitor being studied to treat patients with desmoid tumors.

Ayala Pharmaceuticals’ AL102 Granted Orphan Drug Designation by FDA

Surge acted as a precursor for the RSV-marketed drug landscape in 2023, says GlobalData.

RSV Designations Reached All-Time High in 2022, Data Shows

Value is attributed to the rise in counterfeit cases and ongoing regulations surrounding anti-counterfeit packaging. 

Anti-Counterfeit Packaging Market Estimated to Reach Nearly $436 Million by 2030

Pharma Commerce converges on Nation's Capital for HDA Traceability Seminar.

Drilling Down On Distribution

The agency differentiates between software that has a notable impact on the effectiveness and safety of drug use.

Legal and Regulatory